BioStem Technologies, Inc. (BSEM)
| Market Cap | 79.45M -44.7% |
| Revenue (ttm) | 47.48M -84.3% |
| Net Income | -6.58M |
| EPS | -0.39 |
| Shares Out | 16.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 22,096 |
| Average Volume | 62,879 |
| Open | 4.600 |
| Previous Close | 4.680 |
| Day's Range | 4.400 - 4.750 |
| 52-Week Range | 3.093 - 15.500 |
| Beta | 0.18 |
| RSI | 44.02 |
| Earnings Date | Mar 24, 2026 |
About BioStem Technologies
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human conne... [Read more]
Financial Performance
Financial StatementsNews
BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair
SEC-Qualified Financial Expert and Life Sciences Veteran Brings 29 Years of Accounting Leadership to the Board SEC-Qualified Financial Expert and Life Sciences Veteran Brings 29 Years of Accounting Le...
BioTissue Holdings, Inc Strengthens Strategic Focus on Ocular Innovation with Sale of Surgical and Wound Care Business to BioStem Technologies
BioTissue Deepens Commitment to Ocular Market Leadership MIAMI, Jan. 21, 2026 /PRNewswire/ -- BioTissue Holdings, Inc, a leader in harnessing the unique properties of human birth tissue to facilitate ...
BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant
POMPANO BEACH, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (the “Company”), a leading MedTech company focused on the development, manufacturing, and commercializatio...
BioStem Announces Notice of Allowance for Two U.S. Patent Applications
POMPANO BEACH, Fla., March 31, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-...
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®
POMPANO BEACH, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-d...
BioStem Technologies CEO to Present at Biotech Showcase 2025
POMPANO BEACH, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-d...
BioStem Technologies to Present at the LD Micro Main Event XVII on Wednesday, October 30, 2024, at 9:30 AM PT
Presentation to be webcast, with management participating in 1-on-1 meetings at the Luxe Sunset Boulevard Hotel in Los Angeles Pompano Beach, Florida--(Newsfile Corp. - October 23, 2024) - BioStem Tec...
BioStem Technologies, Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET
POMPANO BEACH, Fla., Aug. 29, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-der...
BioStem Technologies Inc. In A Race To The Top With Innovative Wound-Care Treatments
Miami, Florida--(Newsfile Corp. - July 16, 2024) - Innovation is the lifeblood of the MedTech sector. Literally.
UPDATE -- PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion
Please note: this Update is being issued for ticker indexing purposes. The content of the release itself remains the same.
PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion
NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an exclusive interview with Jason Matuszewski, CEO of BioStem Technologies, Inc. ( OTC: BSEM). Following a successful start to 20...
BioStem Technologies Retains Clinical Research Industry Veteran Nick McCoy to Lead DFU and VLU trials for BioREtain Allografts
POMPANO BEACH, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Center for Medicare Services Established National Pricing of AmnioWrap2™ in All MAC Regions
POMPANO BEACH, Fla., Dec. 14, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of ...
NovaBay Pharmaceuticals Announces Commercial Launch of Avenova® Allograft
EMERYVILLE, Calif. & POMPANO BEACH, Fla.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces the commercial launch of Avenova Allograft to eyecare professionals across the U...
NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft
EMERYVILLE, Calif. & POMPANO BEACH, Fla.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and BioStem Technologies, Inc. (OTC: BSEM) announce an agreement under which NovaBay has b...
BioStem Awarded a Spot on ECAT, DAPA, and FSS Contract Vehicles Through SDVOSB, Lovell
PENSACOLA, FL, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Lovell® Government Services (‘Lovell') and BioStem Technologies (POMPANO BEACH, FL, ‘BioStem') announced today that they have successfully listed BioS...
BioStem Technologies Commends OIG's Recommendation for CMS to Address ASP Reporting Requirements for Skin Substitute Products
POMPANO BEACH, FLORIDA., March 23, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies (“BioStem” or the “Company”) (OTCQB: BSEM), a leading provider of innovative regenerative medicine solutions, is commen...
BioStem Technologies to Acquire Majority of Assets of Auxocell Laboratories, Inc.
POMPANO BEACH, FLORIDA., March 07, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (“BioStem” or the “Company”) (OTCQB: BSEM), announced today that it has entered into an Agreement to acquire the m...
BioStem Technologies Enters Into a Share Exchange Agreement
The Company will Acquire Back 10% of Issued and Outstanding Shares of its Non-Wholly Owned Subsidiary and Manufacturing Division
BioStem Technologies Poised for Growth with Two New Hires: Michael Sylvester Joins as Vice President of Sales, Neal Bhattacharya as Vice President of Marketing
POMPANO BEACH, FLORIDA., Feb. 01, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (“BioStem” or the “Company) (OTCQB: BSEM), a leading regenerative medicine company focused on the development, manu...
Center for Medicare Services Established National Pricing of VENDAJETM in All MAC regions
Pricing Provides VENDAJE TM Reimbursement in A ll MAC R egions
BioStem Technologies Announces Up-Listing to the OTCQB Venture Market
POMPANO BEACH, FLORIDA., Dec. 16, 2022 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTCQB: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercializati...
BioStem Technologies Announces Partnership with Kill Cliff FC
Kill Cliff FC is One of the world's largest MMA Training Centers with More T han 80 P rofessional F ighters
BioStem Technologies Reports Third Quarter 2022 Operating and Financial Results
Company to Host a Conference Call and Webcast on November 15 , 2022, at 4:30 pm EDT
BioStem Technologies to Host Third Quarter Financial Results and Corporate Update Conference Call
POMPANO BEACH, FLORIDA., Nov. 15, 2022 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization...